Scarica l'app Stockscreener
23.41
0.38%
-0.09
Pre-mercato:
23.51
0.10
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$23.50
Aprire:
$23.35
Volume 24 ore:
575.78K
Relative Volume:
0.65
Capitalizzazione di mercato:
$3.37B
Reddito:
$340.81M
Utile/perdita netta:
$-419.65M
Rapporto P/E:
-8.214
EPS:
-2.85
Flusso di cassa netto:
$-402.10M
1 W Prestazione:
+0.43%
1M Prestazione:
+13.59%
6M Prestazione:
-3.98%
1 anno Prestazione:
+33.62%
Intervallo 1D:
$23.15
$23.79
Intervallo di 1 settimana:
$21.85
$23.79
Portata 52W:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8548
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Confronta DNLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
23.41 | 3.37B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.52 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.27 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
654.76 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.99 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.16 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
The Goldman Sachs Group Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
Analysts Set Expectations for DNLI FY2025 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - Yahoo Finance
Short Interest in Denali Therapeutics Inc. (NASDAQ:DNLI) Grows By 5.1% - MarketBeat
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
JPMorgan Chase & Co. Purchases 14,324 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Denali Therapeutics sees cash runway into 2028 - MSN
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 9.8%Still a Buy? - MarketBeat
Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair - MarketBeat
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - MSN
Denali Therapeutics Announces Key Anticipated 2025 - GlobeNewswire
Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - StockTitan
Denali Therapeutics Outlines 2025 Milestones and Strategies - TipRanks
Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome - MSN
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock By Investing.com - Investing.com Nigeria
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More - MSN
Denali Therapeutics director Steve Krognes sells $69,484 in stock By Investing.com - Investing.com Australia
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock By Investing.com - Investing.com South Africa
HC Wainwright Has Positive Forecast for DNLI FY2026 Earnings - MarketBeat
Denali therapeutics’ CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com Nigeria
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com Canada
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 - Investing.com India
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock - Investing.com India
Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares - MarketBeat
Ryan J. Watts Sells 29,266 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock - MarketBeat
Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,339 Shares of Stock - MarketBeat
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock - Investing.com
Denali Therapeutics director Steve Krognes sells $69,484 in stock - Investing.com
Denali Therapeutics stock maintains buy rating on FDA decision By Investing.com - Investing.com Canada
Denali Therapeutics (NASDAQ:DNLI) Trading Up 3.1%Here's What Happened - MarketBeat
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - BioPharma Dive
Denali Therapeutics stock maintains buy rating on FDA decision - Investing.com
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases - BioSpace
Research Analysts Offer Predictions for DNLI FY2028 Earnings - MarketBeat
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Marketscreener.com
Denali receives FDA breakthrough status for Hunter syndrome drug - Investing.com India
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
9.39%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):